Processa Pharmaceuticals Inc

NASDAQ:PCSAUnited States

Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on development of drug products that are intended to provide treatment for patients who have unmet medical need condition that effects survival or the patient’s life and no treatment options. It has five drugs: four in various stages of clinical development (PCS499, PCS12852, PCS3117 and PCS6422) and one in nonclinical development (PCS11T). PCS499 is an oral tablet that is a deuterated analog of one of the major metabolites of pentoxifylline (PTX ). PCS12852 is a highly specific and potent 5-hydroxytryptamine 4 (5-HT4) receptor agonist. is a novel, investigational, oral small molecule nucleoside compound. PCS3117 is an analog of the endogenous nucleoside, cytidine, and an analog of the cancer drug gemcitabine. PCS6422 is an oral, potent, selective and irreversible inhibitor of dihydropyrimidine dehydrogenase (DPD). PCS11T is being developed for the treatment of the solid tumor.

Contact Information

Headquarters

7380 Coca Cola Dr Ste 106HANOVER, MD, United States 21076-1789

Phone

443-776-3133

Fax

443-288-4420

Executives

Independent Chairman of the Board

Justin Yorke

Chief Executive Officer, Director

David Young

Founder, Chief Administrative Officer

Wendy Guy

Chief Development Officer, Founder

Sian Bigora

Chief Financial Officer

James Stanker